clinical-trials

Started tirzepatide in February. Nothing unusual until early June, when the shedding started, and it is now substantial: handfuls in the shower, hair on the pillow,…

Every summary I read says nausea is "the most common adverse event" and then quotes a single percentage, usually without saying which trial, which dose or which…

I am going to have to stop, not by choice: my supply arrangement is ending and the alternative is not affordable for me long term. I have gone from 108 kg to 79 kg…

The phrase "food noise" is used constantly and I have never seen it defined precisely. My own experience of it was extremely specific and I would like to know what it…

I am five months in, down 16 kg, and flattened. Not sleepy, exactly. More that everything costs more than it used to: stairs, conversations, training sessions I used…

The claim that "about a quarter of what you lose on these drugs is muscle" gets repeated everywhere and I have never once seen it sourced. I am 14 weeks into…

I started semaglutide for weight and something I did not expect happened: I stopped drinking, more or less by accident. I was on four or five drinks most evenings for…

For reference: 5 mg · survodutide. I would like to define my thresholds before I have a result, for obvious reasons. I want a plan with explicit stopping rules, not…

The specifics, since they change the answer: vomiting · retatrutide · TRIUMPH-3. I have the document in front of me and I can read the numbers. What I cannot do is…

The particulars: STEP 1 · hair thinning. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably…

Concretely: SELECT · semaglutide. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is that I am being…

What I have: mazdutide · room temperature. I am asking for verification rather than opinion, ideally with something I can read myself. It is possible the evidence…

The particulars: liraglutide · minus 20 °C. I would like to know whether this claim survives contact with evidence. If the answer is "nobody has tested that", I would…

The clinician who ordered the panel was not concerned; I would still like to understand it. Please show the division. I want to check my own against yours. I would…

The case in front of me: ecnoglutide · 2–8 °C. The claim is plausible, which is exactly why I want to check it. I am able to read a paper if someone points me at one.…

Conditions: FLOW · 2.4 mg. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a single result, which I have…

Conditions: constipation · oral semaglutide · PIONEER-4. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers…

Stated plainly: SURPASS-3 · a GLP-1 receptor agonist. I would like help reading this properly rather than being told what conclusion to reach. I have the full report…

Setup, so nobody has to ask: STEP 1 · a GLP-1 receptor agonist. This has the shape of a fact but I cannot find its origin. What I found instead were three secondary…

The case in front of me: three weeks · mazdutide. This is asserted often enough that I assumed it was established, and then I went looking for the source. I have…

For reference: semaglutide · liraglutide. These are treated as interchangeable and I do not think they are. If both are acceptable I would like to know that, so I can…

This came up because two published schedules for the same agent differ. I would like to know the limits of what can be inferred from this. What I am trying to avoid…

Details up front: SOUL · 25 mg. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s interpretation…

I am asking about the protocol logic rather than about my own case specifically. I would like to know whether this claim survives contact with evidence. If the answer…